MED1

Mediator of RNA polymerase II transcription subunit 1 · Q15648 · MED1 on Sugi Atlas →

0 patent compounds predicted against MED1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to MED1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma PHASE2COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Spironolactone and XPB-1 Integrity in the TFIIH Complex nanENROLLING_BY_INVITATION
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma nanCOMPLETED
miR-155 Expression in Episodic and Chronic Migraine nanUNKNOWN
The Difference of microRNA and Circulating Tumor Cells in Blood Among Cancer Patients With Immunotherapy nanRECRUITING
Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts nanCOMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED
Immune Interactions in Severe Asthma nanCOMPLETED
Na+ Channel mRNA Regulation in Heart Failure nanCOMPLETED
Methylation of DNA in Children and Adolescents With Type 1 Diabetes Mellitus (METHYLDIAB) nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis nanCOMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation nanUNKNOWN
Family Resilience Initiative Research Program nanUNKNOWN
Maternal Hypertriglyceridaemia Study nanUNKNOWN
EKLF Gene Expression in β-thalassemia nanNOT_YET_RECRUITING
A Comparison of p53-induced Genes Activation in Patients With and Without Acute Myocardial Infarction nanCOMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MED1 binder may also engage these)

ProteinNameSimilarity
Q6INP8 1.000 Q6INP8 →
Q5RES4 1.000 Q5RES4 →
Q925J9 1.000 Q925J9 →
A1L0Z0 1.000 A1L0Z0 →
Q172G3 0.992 Q172G3 →
Q9VP05 0.992 Q9VP05 →
Q09YG9 0.992 Q09YG9 →
Q9NZN8 0.991 Q9NZN8 →
Q09YJ3 0.991 Q09YJ3 →
SMARCC2 SWI/SNF complex subunit SMARCC2 0.991 landscape →
NFRKB Nuclear factor related to kappa-B-binding protein 0.991 landscape →
Q9JJP2 0.990 Q9JJP2 →
Q2IBE6 0.990 Q2IBE6 →
Q9XSK8 0.990 Q9XSK8 →
B5DF21 0.990 B5DF21 →
A5D794 0.990 A5D794 →
Q2IBA2 0.990 Q2IBA2 →
Q07E15 0.990 Q07E15 →
O43439 0.990 O43439 →
Q6PAR5 0.989 Q6PAR5 →
Q8WZ74 0.989 Q8WZ74 →
Q09YK4 0.989 Q09YK4 →
Q2IBF8 0.989 Q2IBF8 →
Q5PRF9 0.989 Q5PRF9 →
A0M8T5 0.989 A0M8T5 →
Q6GN21 0.989 Q6GN21 →
P91621 0.989 P91621 →
P41846 0.989 P41846 →
Q09YI1 0.989 Q09YI1 →
A0M8S4 0.988 A0M8S4 →